Organigram Global Inc. (OGI) is betting that Europe represents the next major chapter in cannabis legalization, and it's putting serious money behind that thesis. The Canadian cannabis company announced Wednesday it's acquiring Sanity Group, a leading German cannabis operator, in a deal that could reach nearly $248 million if earnout targets are hit.
The move aims to transform Organigram from a North American cannabis company into a genuine global player with meaningful market positions on both sides of the Atlantic.
Breaking Down The Numbers
Here's how the deal shakes out: Organigram will pay Sanity shareholders 113.4 million euros (roughly $134 million) upfront. That breaks down into 80 million euros in cash and 33.4 million euros in Organigram shares.
But there's more. Sanity shareholders could receive up to an additional 113.8 million euros in earnout payments tied to future performance. The first 20 million euros of that earnout would come in cash, with the remaining 93.8 million euros potentially paid in Organigram stock.
An interesting twist: British American Tobacco plc (BTI) owns stakes in both companies and has chosen to receive Organigram shares instead of cash for its Sanity holdings. That's a vote of confidence worth noting.
How They're Paying For It
Organigram plans to finance the acquisition through a mix of cash reserves, a new credit facility, and fresh equity investment. The company is in advanced talks with British American Tobacco for a 65.2 million Canadian dollar investment (around $47.8 million) to help cover the cash portion of the deal.
Why This Deal Matters
"By combining our strengths as focused cannabis pure play companies, we will be well-positioned to deliver meaningful value for our shareholders and accelerate growth in key European markets," said Paolo De Luca, Chief Strategy Officer at Organigram.
CEO James Yamanaka framed it even more ambitiously: "This transformational acquisition will bring together two market leaders, extend our commercial footprint into Europe, and strengthen our competitive edge in the world's largest federally legal cannabis markets."
The company expects the acquisition to be financially accretive, adding scale while supporting revenue growth and profitability. Notably, Sanity has already achieved positive EBITDA in 2025, which suggests this isn't just a speculative bet on future legalization.
What The Charts Say
Despite Wednesday's premarket pop, Organigram stock has been struggling. Shares are trading 13.3% below their 20-day simple moving average and 21.8% below their 100-day SMA, indicating bearish momentum in both the short and medium term. The stock has dropped 6.62% over the past year and sits closer to its 52-week lows than highs.
Technical indicators paint a mixed picture. The RSI sits at 31.75, which is neutral territory, while the MACD remains below its signal line, suggesting continued bearish pressure. The combination indicates momentum could swing either way.
- Key Resistance: $1.50
- Key Support: $1.00
OGI Price Action: Organigram Global shares jumped 7.09% to $1.36 during premarket trading on Wednesday.
